Skip to content
2000
image of Navigating through Neuropathic Pain: From Pathophysiology to Present and Future Treatments

Abstract

Neuropathic pain (NP) results from lesions or malfunctions in the somatosensory nervous system. Neuropathic pain is a multifaceted health condition that currently lacks a universally accepted classification system or definitive biomarkers for diagnosis. Based upon its origin, NP is categorized into peripheral and central neuropathic pain. Different symptoms, both positive and negative, accompany accompany NP. Currently, pain mechanism models, including spared nerve injury (SNI) and chronic constriction injury (CCI) models, are utilized to investigate neuropathic pain. Despite increasing research on NP, a definitive cure remains elusive; management is primarily symptomatic, relying on contemporary therapeutic approaches, such as anti-inflammatory drugs (., methylprednisolone acetate), anticonvulsants (., gabapentin, pregabalin), antidepressants (., amitriptyline), and topical agents (., lidocaine). However, neuropathic pain affects approximately 7–10% of the global population, with less than 50% of patients achieving satisfactory relief with existing therapies, underscoring the need for novel therapeutic strategies. Novel therapies, including the repurposing of established medications, such as cannabidiol (CBD), are emerging and have great potential to become a new class of anti-neuropathic pain drug. Advanced clinical interventional approaches encompassing invasive procedures like spinal cord stimulation (SCS), deep brain stimulation (DBS), and percutaneous neuromodulation therapy (PENS), along with the promise of regenerative therapies, including gene therapy, are also being developed and improved for the long-term alleviation of NP; all these are being discussed in this article.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266417188251106114042
2026-02-10
2026-02-25

  • From This Site

    /content/journals/ctmc/10.2174/0115680266417188251106114042
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Lindblom U. Merskey H. Mumford J.M. Nathan P.W. Noordenbos W. Sunderland S.S. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl. 1986 24 S215 S221 10.1016/0304‑3959(86)90113‑2
    [Google Scholar]
  2. Fitzcharles M.A. Cohen S.P. Clauw D.J. Littlejohn G. Usui C. Häuser W. Nociplastic pain: Towards an understanding of prevalent pain conditions. Lancet 2021 397 10289 2098 2110 10.1016/S0140‑6736(21)00392‑5 34062144
    [Google Scholar]
  3. Treede R.D. Jensen T.S. Campbell J.N. Cruccu G. Dostrovsky J.O. Griffin J.W. Hansson P. Hughes R. Nurmikko T. Serra J. Neuropathic pain. Neurology 2008 70 18 1630 1635 10.1212/01.wnl.0000282763.29778.59 18003941
    [Google Scholar]
  4. Jayakar S. Shim J. Jo S. Bean B.P. Singeç I. Woolf C.J. Developing nociceptor-selective treatments for acute and chronic pain. Sci. Transl. Med. 2021 13 619 eabj9837 10.1126/scitranslmed.abj9837 34757806
    [Google Scholar]
  5. Jensen T.S. Baron R. Haanpää M. Kalso E. Loeser J.D. Rice A.S.C. Treede R.D. A new definition of neuropathic pain. Pain 2011 152 10 2204 2205 Oct 10.1016/j.pain.2011.06.017 21764514
    [Google Scholar]
  6. Pan J. Toro C.A. Chow C. Duarte Y. Sáez J.C. Cardozo C.P. Zhao W. Oral administration of boldine reduces spare nerve injury-induced neuropathic pain. bioRxiv 2025 2024.2011.2005.622128 10.1101/2024.11.05.622128
    [Google Scholar]
  7. Bouhassira D. Attal N. Alchaar H. Boureau F. Brochet B. Bruxelle J. Cunin G. Fermanian J. Ginies P. Grun-Overdyking A. Jafari-Schluep H. Lantéri-Minet M. Laurent B. Mick G. Serrie A. Valade D. Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005 114 1 29 36 10.1016/j.pain.2004.12.010 15733628
    [Google Scholar]
  8. Finnerup N.B. Kuner R. Jensen T.S. Neuropathic pain: From mechanisms to treatment. Physiol. Rev. 2021 101 1 259 301 10.1152/physrev.00045.2019 32584191
    [Google Scholar]
  9. Baron R. Neuropathic pain: A clinical perspective. Handb. Exp. Pharmacol. 2009 2009 3 30 10.1007/978‑3‑540‑79090‑7_1 19655103
    [Google Scholar]
  10. Decosterd I. Woolf C.J. Spared nerve injury: An animal model of persistent peripheral neuropathic pain. Pain 2000 87 2 149 158 10.1016/S0304‑3959(00)00276‑1 10924808
    [Google Scholar]
  11. Challa S.R. Surgical animal models of neuropathic pain: Pros and cons. Int. J. Neurosci. 2015 125 3 170 174 10.3109/00207454.2014.922559 24831263
    [Google Scholar]
  12. Cheng Z. Feng S. Yang L. Huang J. Chen X. Guo Y. Xiang Y. Peng B. Rat model of neuropathic pain induced by spinal nerve ligation: A new approach via an oblique lateral incision. J. Pain Res. 2024 17 2443 2454 10.2147/JPR.S452344 39070852
    [Google Scholar]
  13. Chung J.M. Chung K. Neuropathic pain model, spinal nerve ligation model. Encyclopedia of Pain. Schmidt R.F. Willis W.D. Springer Berlin Heidelberg 2007 1303 1306 10.1007/978‑3‑540‑29805‑2_2683
    [Google Scholar]
  14. Gritsch S. Bali K.K. Kuner R. Vardeh D. Functional characterization of a mouse model for central post-stroke pain. Mol. Pain 2016 12 1744806916629049 10.1177/1744806916629049 27030713
    [Google Scholar]
  15. Frank T. Nawroth P. Kuner R. Structure–function relationships in peripheral nerve contributions to diabetic peripheral neuropathy. Pain 2019 160 1 S29 S36 10.1097/j.pain.0000000000001530 31008847
    [Google Scholar]
  16. Feldman E.L. Nave K.A. Jensen T.S. Bennett D.L.H. New horizons in Diabetic neuropathy: Mechanisms, bioenergetics, and pain. Neuron 2017 93 6 1296 1313 10.1016/j.neuron.2017.02.005 28334605
    [Google Scholar]
  17. Hozumi J. Sumitani M. Matsubayashi Y. Abe H. Oshima Y. Chikuda H. Takeshita K. Yamada Y. Relationship between neuropathic pain and obesity. Pain Res. Manag. 2016 2016 1 6 10.1155/2016/2487924 27445603
    [Google Scholar]
  18. Godai K. Takahashi K. Kashiwagi Y. Liu C.H. Yi H. Liu S. Dong C. Lubarsky D.A. Hao S. Ryanodine receptor to mitochondrial reactive oxygen species pathway plays an important role in chronic human immunodeficiency virus gp120MN-induced neuropathic pain in rats. Anesth. Analg. 2019 129 1 276 286 10.1213/ANE.0000000000003916 30507840
    [Google Scholar]
  19. Silva J.R. Lopes A.H. Talbot J. Cecilio N.T. Rossato M.F. Silva R.L. Souza G.R. Silva C.R. Lucas G. Fonseca B.A. Arruda E. Alves-Filho J.C. Cunha F.Q. Cunha T.M. Neuroimmune–Glia interactions in the sensory ganglia account for the development of acute herpetic neuralgia. J. Neurosci. 2017 37 27 6408 6422 10.1523/JNEUROSCI.2233‑16.2017 28576938
    [Google Scholar]
  20. Pitzer C. Kuner R. Tappe-Theodor A. Voluntary and evoked behavioral correlates in neuropathic pain states under different social housing conditions. Mol. Pain 2016 12 1744806916656635 10.1177/1744806916656635 27306409
    [Google Scholar]
  21. Tappe-Theodor A. King T. Morgan M.M. Pros and cons of clinically relevant methods to assess pain in rodents. Neurosci. Biobehav. Rev. 2019 100 335 343 10.1016/j.neubiorev.2019.03.009 30885811
    [Google Scholar]
  22. Mao J. Current challenges in translational pain research. Trends Pharmacol. Sci. 2012 33 11 568 573 10.1016/j.tips.2012.08.001 22959652
    [Google Scholar]
  23. Meijs S. Hayward A.J. Gomes Nørgaard Dos Santos Nielsen T. Reidies Bjarkam C. Jensen W. Spared ulnar nerve injury results in increased layer III–VI excitability in the pig somatosensory cortex. Lab. Anim. 2024 53 10 287 293 10.1038/s41684‑024‑01440‑0 39349800
    [Google Scholar]
  24. Mogil J.S. Animal models of pain: progress and challenges. Nat. Rev. Neurosci. 2009 10 4 283 294 10.1038/nrn2606 19259101
    [Google Scholar]
  25. Mogil J.S. The translatability of pain across species. Philos. Trans R Soc. Lond B Biol. Sci. 2019 374 1785 20190286 10.1098/rstb.2019.0286 31544615
    [Google Scholar]
  26. Yordanova J. Nicolardi V. Malinowski P. Simione L. Aglioti S.M. Raffone A. Kolev V. EEG oscillations reveal neuroplastic changes in pain processing associated with long-term meditation. Sci. Rep. 2025 15 1 10604 10.1038/s41598‑025‑94223‑7 40148498
    [Google Scholar]
  27. Bernatoniene J. Sciupokas A. Kopustinskiene D.M. Petrikonis K. Novel drug targets and emerging pharmacotherapies in neuropathic pain. Pharmaceutics 2023 15 7 1799 10.3390/pharmaceutics15071799 37513986
    [Google Scholar]
  28. Zhou H.Y. Chen S.R. Pan H.L. Targeting N -methyl- D -aspartate receptors for treatment of neuropathic pain. Expert Rev. Clin. Pharmacol. 2011 4 3 379 388 10.1586/ecp.11.17 21686074
    [Google Scholar]
  29. Li L. Chen J. Li Y.Q. The downregulation of opioid receptors and neuropathic pain. Int. J. Mol. Sci. 2023 24 6 5981 10.3390/ijms24065981 36983055
    [Google Scholar]
  30. Stagg N.J. Mata H.P. Ibrahim M.M. Henriksen E.J. Porreca F. Vanderah T.W. Philip Malan T. Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain model: Role of endogenous opioids. Anesthesiology 2011 114 4 940 948 10.1097/ALN.0b013e318210f880 21386701
    [Google Scholar]
  31. Starowicz K. Malek N. Przewlocka B. Cannabinoid receptors and pain. Wiley Interdiscip. Rev. Membr. Transp. Signal. 2013 2 3 121 132 10.1002/wmts.83
    [Google Scholar]
  32. Manzanares J. Julian M. Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr. Neuropharmacol. 2006 4 3 239 257 10.2174/157015906778019527 18615144
    [Google Scholar]
  33. Lee K. Jo Y.Y. Chung G. Jung J.H. Kim Y.H. Park C.K. Functional importance of Transient Receptor Potential (TRP) channels in neurological disorders. Front. Cell Dev. Biol. 2021 9 611773 10.3389/fcell.2021.611773 33748103
    [Google Scholar]
  34. McAnally H. Bonnet U. Kaye A.D. Gabapentinoid benefit and risk stratification: Mechanisms over myth. Pain Ther. 2020 9 2 441 452 10.1007/s40122‑020‑00189‑x 32737803
    [Google Scholar]
  35. Li C. Lei Y. Tian Y. Xu S. Shen X. Wu H. Bao S. Wang F. The etiological contribution of GABAergic plasticity to the pathogenesis of neuropathic pain. Mol. Pain 2019 15 1744806919847366 10.1177/1744806919847366 30977423
    [Google Scholar]
  36. Casey A.B. Cui M. Booth R.G. Canal C.E. “Selective” serotonin 5-HT2A receptor antagonists. Biochem. Pharmacol. 2022 200 115028 10.1016/j.bcp.2022.115028 35381208
    [Google Scholar]
  37. Vahid-Ansari F. Zhang M. Zahrai A. Albert P.R. Overcoming resistance to selective serotonin reuptake inhibitors: Targeting serotonin, Serotonin-1A receptors and adult neuroplasticity. Front. Neurosci. 2019 13 404 10.3389/fnins.2019.00404 31114473
    [Google Scholar]
  38. Hayashida K. Obata H. Strategies to treat chronic pain and strengthen impaired descending noradrenergic inhibitory system. Int. J. Mol. Sci. 2019 20 4 822 10.3390/ijms20040822 30769838
    [Google Scholar]
  39. Mannelli L. Micheli L. Crocetti L. Giovannoni M. Vergelli C. Ghelardini C. α 2 Adrenoceptor: A target for neuropathic pain treatment. Mini Rev. Med. Chem. 2016 17 2 95 107 10.2174/1389557516666160609065535
    [Google Scholar]
  40. Yalcin I. Tessier L.H. Petit-Demoulière N. Waltisperger E. Hein L. Freund-Mercier M.J. Barrot M. Chronic treatment with agonists of β2-adrenergic receptors in neuropathic pain. Exp. Neurol. 2010 221 1 115 121 10.1016/j.expneurol.2009.10.008 19840789
    [Google Scholar]
  41. Zou Y. Yang R. Li L. Xu X. Liang S. Purinergic signaling: A potential therapeutic target for depression and chronic pain. Purinergic Signal. 2023 19 1 163 172 10.1007/s11302‑021‑09801‑x 34338957
    [Google Scholar]
  42. Zhou M. Wu J. Chang H. Fang Y. Zhang D. Guo Y. Adenosine signaling mediate pain transmission in the central nervous system. Purinergic Signal. 2023 19 1 245 254 10.1007/s11302‑021‑09826‑2 35000074
    [Google Scholar]
  43. St John Smith E. Advances in understanding nociception and neuropathic pain. J. Neurol. 2018 265 2 231 238 10.1007/s00415‑017‑8641‑6 29032407
    [Google Scholar]
  44. Benarroch E.E. Ion channels in nociceptors. Neurology 2015 84 11 1153 1164 10.1212/WNL.0000000000001382 25713000
    [Google Scholar]
  45. Chen Y. Wu Q. Jin Z. Qin Y. Meng F. Zhao G. Review of voltage-gated calcium channel α2δ subunit ligands for the treatment of chronic neuropathic pain and insight into Structure-activity Relationship (SAR) by pharmacophore modeling. Curr. Med. Chem. 2022 29 30 5097 5112 10.2174/0929867329666220407093727 35392779
    [Google Scholar]
  46. Schrenk-Siemens K. Rösseler C. Lampert A. Translational model systems for complex sodium channel pathophysiology in pain. Handb. Exp. Pharmacol. 2018 246 355 369 10.1007/164_2017_91
    [Google Scholar]
  47. Sacerdote P. Franchi S. Moretti S. Castelli M. Procacci P. Magnaghi V. Panerai A.E. Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain. J. Neuroimmune Pharmacol. 2013 8 1 202 211 10.1007/s11481‑012‑9428‑2 23242694
    [Google Scholar]
  48. Vincenzi M. Milella M.S. D’Ottavio G. Caprioli D. Reverte I. Maftei D. Targeting chemokines and chemokine GPCRs to enhance strong opioid efficacy in neuropathic pain. Life 2022 12 3 398 10.3390/life12030398 35330149
    [Google Scholar]
  49. Gui W.S. Wei X. Mai C.L. Murugan M. Wu L.J. Xin W.J. Zhou L.J. Liu X.G. Interleukin-1β overproduction is a common cause for neuropathic pain, memory deficit, and depression following peripheral nerve injury in rodents. Mol. Pain 2016 12 1744806916646784 10.1177/1744806916646784 27175012
    [Google Scholar]
  50. Hingtgen C.M. Waite K.J. Vasko M.R. Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3′,5′-cyclic monophosphate transduction cascade. J. Neurosci. 1995 15 7 Pt 2 5411 5419 10.1523/JNEUROSCI.15‑07‑05411.1995 7623163 PMC6577886
    [Google Scholar]
  51. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 2004 63 9 901 910 10.1093/jnen/63.9.901 15453089
    [Google Scholar]
  52. Ji R.R. Xu Z.Z. Wang X. Lo E.H. Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol. Sci. 2009 30 7 336 340 10.1016/j.tips.2009.04.002 19523695
    [Google Scholar]
  53. Ghosh K. Pan H.L. Epigenetic mechanisms of neural plasticity in chronic neuropathic pain. ACS Chem. Neurosci. 2022 13 4 432 441 10.1021/acschemneuro.1c00841 35107991
    [Google Scholar]
  54. Fransson R. Botros M. Nyberg F. Lindeberg G. Sandström A. Hallberg M. Small peptides mimicking substance P (1–7) and encompassing a C-terminal amide functionality. Neuropeptides 2008 42 1 31 37 10.1016/j.npep.2007.11.002 18093649
    [Google Scholar]
  55. Fransson R. Botros M. Sköld C. Nyberg F. Lindeberg G. Hallberg M. Sandström A. Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J. Med. Chem. 2010 53 6 2383 2389 10.1021/jm901352b 20178322
    [Google Scholar]
  56. Igwe O.J. Kim D.C. Seybold V.S. Larson A.A. Specific binding of substance P aminoterminal heptapeptide [SP(1-7)] to mouse brain and spinal cord membranes. J. Neurosci. 1990 10 11 3653 3663 10.1523/JNEUROSCI.10‑11‑03653.1990 1700082
    [Google Scholar]
  57. Minn Y.K. Kim S.M. Diagnosis and treatment of neuropathic pain. J. Korean Med. Assoc. 2008 51 12 1139 1148 10.5124/jkma.2008.51.12.1139
    [Google Scholar]
  58. Kramer M.S. Cutler N. Feighner J. Shrivastava R. Carman J. Sramek J.J. Reines S.A. Liu G. Snavely D. Wyatt-Knowles E. Hale J.J. Mills S.G. MacCoss M. Swain C.J. Harrison T. Hill R.G. Hefti F. Scolnick E.M. Cascieri M.A. Chicchi G.G. Sadowski S. Williams A.R. Hewson L. Smith D. Carlson E.J. Hargreaves R.J. Rupniak N.M.J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998 281 5383 1640 1645 10.1126/science.281.5383.1640 9733503
    [Google Scholar]
  59. Kreeger J.S. Larson A.A. The substance P amino-terminal metabolite substance P(1-7), administered peripherally, prevents the development of acute morphine tolerance and attenuates the expression of withdrawal in mice. J. Pharmacol. Exp. Ther. 1996 279 2 662 667 10.1016/S0022‑3565(25)21174‑0 8930169
    [Google Scholar]
  60. Caroleo M.C. Brizzi A. De Rosa M. Pandey A. Gallelli L. Badolato M. Carullo G. Cione E. Targeting neuropathic pain: Pathobiology, current treatment and peptidomimetics as a new therapeutic opportunity. Curr. Med. Chem. 2020 27 9 1469 1500 10.2174/0929867326666190530121133 31142248
    [Google Scholar]
  61. Vali R. Azadi A. Tizno A. Farkhondeh T. Samini F. Samarghandian S. miRNA contributes to neuropathic pains. Int. J. Biol. Macromol. 2023 253 Pt 4 126893 10.1016/j.ijbiomac.2023.126893 37730007
    [Google Scholar]
  62. García-Domínguez M. NGF in neuropathic pain: Understanding its role and therapeutic opportunities. Curr. Issues Mol. Biol. 2025 47 2 93 10.3390/cimb47020093 39996814
    [Google Scholar]
  63. Schou W.S. Ashina S. Amin F.M. Goadsby P.J. Ashina M. Calcitonin gene-related peptide and pain: A systematic review. J. Headache Pain 2017 18 1 34 10.1186/s10194‑017‑0741‑2 28303458
    [Google Scholar]
  64. Yawn B.P. Wollan P.C. Weingarten T.N. Watson J.C. Hooten W.M. Melton L.J. The prevalence of neuropathic pain: Clinical evaluation compared with screening tools in a community population. Pain Med. 2009 10 3 586 593 10.1111/j.1526‑4637.2009.00588.x 20849570
    [Google Scholar]
  65. Bouhassira D. Lantéri-Minet M. Attal N. Laurent B. Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008 136 3 380 387 10.1016/j.pain.2007.08.013 17888574
    [Google Scholar]
  66. Van Acker K. Bouhassira D. De Bacquer D. Weiss S. Matthys K. Raemen H. Mathieu C. Colin I.M. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009 35 3 206 213 10.1016/j.diabet.2008.11.004 19297223
    [Google Scholar]
  67. Ryder S.A. Stannard C.F. Treatment of chronic pain: Antidepressant, antiepileptic and antiarrhythmic drugs. Contin. Educ. Anaesth. Crit. Care Pain 2005 5 1 18 21 10.1093/bjaceaccp/mki003
    [Google Scholar]
  68. Rauck R.L. Shaibani A. Biton V. Simpson J. Koch B. Lacosamide in painful diabetic peripheral neuropathy: A phase 2 double-blind placebo-controlled study. Clin. J. Pain 2007 23 2 150 158 10.1097/01.ajp.0000210957.39621.b2 17237664
    [Google Scholar]
  69. Beyreuther B.K. Callizot N. Brot M.D. Feldman R. Bain S.C. Stöhr T. Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. Eur. J. Pharmacol. 2007 565 1-3 98 104 10.1016/j.ejphar.2007.02.041 17395176
    [Google Scholar]
  70. Ichimata M. Kitano T. Ikebe H. Iwasaka H. Noguchi T. Flecainide reverses neuropathic pain and suppresses ectopic nerve discharge in rats. Neuroreport 2001 12 9 1869 1873 10.1097/00001756‑200107030‑00021 11435914
    [Google Scholar]
  71. von Gunten C.F. Eappen S. Cleary J.F. Taylor S.G. Moots P. Regevik N. Cleeland C. Cella D. Flecainide for the treatment of chronic neuropathic pain: A Phase II trial. Palliat. Med. 2007 21 8 667 672 10.1177/0269216307083031 18073252
    [Google Scholar]
  72. Pandey M. Singh A.K. Thakare R. Talwar S. Karaulia P. Dasgupta A. Chopra S. Pandey A.K. Diphenyleneiodonium chloride (DPIC) displays broad-spectrum bactericidal activity. Sci. Rep. 2017 7 1 11521 10.1038/s41598‑017‑11575‑5 28912539
    [Google Scholar]
  73. Ji Z.H. Liu Z.J. Liu Z.T. Zhao W. Williams B.A. Zhang H.F. Li L. Xu S.Y. Diphenyleneiodonium mitigates bupivacaine-induced sciatic nerve damage in a Diabetic neuropathy rat model by attenuating oxidative stress. Anesth. Analg. 2017 125 2 653 661 10.1213/ANE.0000000000002186 28682956
    [Google Scholar]
  74. Laddha A.P. Kulkarni Y.A. NADPH oxidase: A membrane-bound enzyme and its inhibitors in diabetic complications. Eur. J. Pharmacol. 2020 881 173206 10.1016/j.ejphar.2020.173206 32442539
    [Google Scholar]
  75. Eker H.E. Cok O.Y. Aribogan A. Arslan G. Management of neuropathic pain with methylprednisolone at the site of nerve injury. Pain Med. 2012 13 3 443 451 10.1111/j.1526‑4637.2011.01323.x 22313580
    [Google Scholar]
  76. Nguyen D.T. Dang T.C. Nguyen Q.A. Le T.D. Hoang T.D. Tran T.N.T. Duong T.H.N. Nguyen V.T. Le V.Q. Hoang T.U. Duong M.T. Nhu D.S. Phan V.N. The effect of subcutaneous injection of methylprednisolone acetate and lidocaine for refractory postherpetic neuralgia: A prospective, observational study. Health Sci. Rep. 2021 4 2 e271 10.1002/hsr2.271 33855194
    [Google Scholar]
  77. Viola V. Newnham H.H. Simpson R.W. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J. Diabetes Complications 2006 20 1 34 39 10.1016/j.jdiacomp.2005.05.007 16389165
    [Google Scholar]
  78. Schafranski M.D. Malucelli T. Machado F. Takeshi H. Kaiber F. Schmidt C. Harth F. Intravenous lidocaine for fibromyalgia syndrome: An open trial. Clin. Rheumatol. 2009 28 7 853 855 10.1007/s10067‑009‑1137‑8 19263182
    [Google Scholar]
  79. Przeklasa-Muszyńska A. Kocot-Kępska M. Dobrogowski J. Wiatr M. Mika J. Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients. Pharmacol. Rep. 2016 68 5 1069 1075 10.1016/j.pharep.2016.06.010 27552062
    [Google Scholar]
  80. Kim Y.C. Castañeda A.M. Lee C. Jin H.S. Park K.S. Moon J.Y. Efficacy and safety of lidocaine infusion treatment for neuropathic pain. Reg. Anesth. Pain Med. 2018 43 4 415 424 10.1097/AAP.0000000000000741 29381569
    [Google Scholar]
  81. Kress H.G. Almeida L. Nunes T. Mota F. Costa R. Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as therapy for subjects with painful diabetic neuropathy: results of BIA-2093-206 phase II study. 2013 Available from:https://clinicaltrials.gov/study/NCT00980746?term=AREA%5BConditionSearch%5D(%22Diabetic%20Neuropathy%22)%20AND%20AREA%5BInterventionSearch%5D(%22Diuretics,%20Potassium%20Sparing%22)=5
    [Google Scholar]
  82. Alcántara Montero A. Sánchez Carnerero C.I. Eslicarbazepine acetate for neuropathic pain, headache, and cranial neuralgia: Evidence and experience. Neurologia 2019 34 6 386 395 10.1016/j.nrleng.2018.10.016 28215909
    [Google Scholar]
  83. Sánchez-Larsen A. Sopelana D. Diaz-Maroto I. Perona-Moratalla A.B. Gracia-Gil J. García-Muñozguren S. Palazón-García E. Segura T. Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia. Eur. J. Pain 2018 22 6 1080 1087 10.1002/ejp.1192 29369456
    [Google Scholar]
  84. Yamamoto S. Suzuki Y. Ono H. Kume K. Ohsawa M. N- and L-type calcium channels blocker cilnidipine ameliorates neuropathic pain. Eur. J. Pharmacol. 2016 793 66 75 10.1016/j.ejphar.2016.11.001 27823932
    [Google Scholar]
  85. Pan C. Wang C. Zhang L. Song L. Chen Y. Liu B. Liu W.T. Hu L. Pan Y. Procyanidins attenuate neuropathic pain by suppressing matrix metalloproteinase-9/2. J. Neuroinflammation 2018 15 1 187 10.1186/s12974‑018‑1182‑9 29929563
    [Google Scholar]
  86. Sternlicht A. Cilnidipine, a novel N-Type specific calcium channel antagonist, has potent activity at the Nav1.7 sodium channel, which may have implications for treatment of certain neuropathic pain conditions (S23.003). Neurology 2023 100 17_issue_2 3813 10.1212/WNL.0000000000203542
    [Google Scholar]
  87. Bagal S.K. Chapman M.L. Marron B.E. Prime R. Storer R.I. Swain N.A. Recent progress in sodium channel modulators for pain. Bioorg. Med. Chem. Lett. 2014 24 16 3690 3699 10.1016/j.bmcl.2014.06.038 25060923
    [Google Scholar]
  88. Kushnarev M. Pirvulescu I.P. Candido K.D. Knezevic N.N. Neuropathic pain: Preclinical and early clinical progress with voltage-gated sodium channel blockers. Expert Opin. Investig. Drugs 2020 29 3 259 271 10.1080/13543784.2020.1728254 32070160
    [Google Scholar]
  89. Preuss C.V. Randhawa G. Wy T.J.P. Oxcarbazepine. StatPearls Internet. Treasure Island, FL StatPearls Publishing 2025
    [Google Scholar]
  90. Demant D.T. Lund K. Vollert J. Maier C. Segerdahl M. Finnerup N.B. Jensen T.S. Sindrup S.H. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 2014 155 11 2263 2273 10.1016/j.pain.2014.08.014 25139589
    [Google Scholar]
  91. Nasreddine W. Beydoun A. Oxcarbazepine in neuropathic pain. Expert Opin. Investig. Drugs 2007 16 10 1615 1625 10.1517/13543784.16.10.1615 17922625
    [Google Scholar]
  92. Carrazana E. Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J. Pain Symptom Manage. 2003 25 5 S31 S35 10.1016/S0885‑3924(03)00067‑8 12694990
    [Google Scholar]
  93. Lalwani K. Shoham A. Koh J.L. McGraw T. Use of oxcarbazepine to treat a pediatric patient with resistant complex regional pain syndrome. J. Pain 2005 6 10 704 706 10.1016/j.jpain.2005.05.005 16202964
    [Google Scholar]
  94. Chaitanya G. Arivazhagan A. Sinha S. Madhusudan Reddy K.R. Thennarasu K. Bharath R.D. Rao M.B. Chandramouli B.A. Satishchandra P. Hemodynamic effects of dexmedetomidine during intra-operative electrocorticography for epilepsy surgery. J. Neurosci. Rural Pract. 2014 5 Suppl 1 S17 S21 10.4103/0976‑3147.145195 25540532
    [Google Scholar]
  95. Gertler R. Brown H.C. Mitchell D.H. Silvius E.N. Dexmedetomidine: A novel sedative-analgesic agent. Proc. Bayl. Univ. Med. Cent. 2001 14 1 13 21 10.1080/08998280.2001.11927725 16369581
    [Google Scholar]
  96. Zhang Y. Zhou Z. Song C. Chen X. The protective effect and mechanism of dexmedetomidine on Diabetic peripheral neuropathy in rats. Front. Pharmacol. 2020 11 1139 10.3389/fphar.2020.01139 32848754
    [Google Scholar]
  97. Liu Y. Liu W. Wang X.Q. Wan Z.H. Liu Y.Q. Zhang M.J. Dexmedetomidine relieves neuropathic pain in rats with chronic constriction injury via the Keap1–Nrf2 pathway. Front. Cell Dev. Biol. 2021 9 714996 10.3389/fcell.2021.714996 34568327
    [Google Scholar]
  98. Lin Y. Wei Y. Wei Y. Yu H. Zhang W. Li C. He Y. Yao G. Zhang Y. Dexmedetomidine alleviates oxidative stress and mitochondrial dysfunction in diabetic peripheral neuropathy via the microRNA-34a/SIRT2/S1PR1 axis. Int. Immunopharmacol. 2023 117 109910 10.1016/j.intimp.2023.109910 37012886
    [Google Scholar]
  99. Yasaei R. Saadabadi A. Clonidine. StatPearls Internet. Treasure Island, FL StatPearls Publishing 2023
    [Google Scholar]
  100. Davis K.D. Treede R.D. Raja S.N. Meyer R.A. Campbell J.N. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain 1991 47 3 309 317 10.1016/0304‑3959(91)90221‑I 1664508
    [Google Scholar]
  101. Byas-Smith M.G. Max M.B. Muir J. Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ design. Pain 1995 60 3 267 274 10.1016/0304‑3959(94)00121‑T 7596622
    [Google Scholar]
  102. Campbell C.M. Kipnes M.S. Stouch B.C. Brady K.L. Kelly M. Schmidt W.K. Petersen K.L. Rowbotham M.C. Campbell J.N. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 2012 153 9 1815 1823 10.1016/j.pain.2012.04.014 22683276
    [Google Scholar]
  103. Mohamed S.A.B. Abdel-Ghaffar H.S. Effect of the addition of clonidine to locally administered bupivacaine on acute and chronic postmastectomy pain. J. Clin. Anesth. 2013 25 1 20 27 10.1016/j.jclinane.2012.05.006 23391342
    [Google Scholar]
  104. Gude R. Patil P. Kamran M.Z. Goel P.N. Development of novel anti-cancer strategies based on angiogenesis inhibition. Anti-Angiogenesis Drug Discovery and Development Atta-ur-Rahman A Choudhary M.I. Elsevier 2014 2 147 190 10.1016/B978‑0‑12‑803963‑2.50005‑3
    [Google Scholar]
  105. Salama R.A.M. Hasanin A.H. Hamza M. Saleh L.A. Habib E.K. Effect of pentoxifylline on Diabetic neuropathic pain in rats. QJM 2021 114 Suppl. 1 hcab114.004 10.1093/qjmed/hcab114.004
    [Google Scholar]
  106. Kalmansohn R.B. Kalmansohn R.W. Markham C.H. Schiff D.L. Treatment of Diabetic neuropathy with pentoxifylline: Case report. Angiology 1988 39 4 371 374 10.1177/000331978803900407 3364803
    [Google Scholar]
  107. Hosseini F. Mohammadbeigi A. Aghaali M. Borujerdi R. Parham M. Effect of pentoxifylline on Diabetic distal polyneuropathy in type 2 Diabetic patients: A randomized trial. J. Res. Med. Sci. 2019 24 1 89 10.4103/jrms.JRMS_115_18 31741661
    [Google Scholar]
  108. Ragavendran J.V. Laferrière A. Bennett G.J. Ware M.A. Gandhi W. Bley K. Schweinhardt P. Coderre T.J. Effects of topical combinations of clonidine and pentoxifylline on capsaicin-induced allodynia and postcapsaicin tourniquet-induced pain in healthy volunteers: A double-blind, randomized, controlled study. Pain 2016 157 10 2366 2374 10.1097/j.pain.0000000000000659 27385502
    [Google Scholar]
  109. Saadabadi A. Fariba K.A. Topiramate. StatPearls[Internet] Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  110. Raskin P. Donofrio P.D. Rosenthal N.R. Hewitt D.J. Jordan D.M. Xiang J. Vinik A.I. Topiramate vs placebo in painful diabetic neuropathy. Neurology 2004 63 5 865 873 10.1212/01.WNL.0000137341.89781.14 15365138
    [Google Scholar]
  111. Fowler J.A. Shen J.Y. Bettinger T.L. Successful use of topiramate in a patient with severe postherpetic neuralgia. Ann. Pharmacother. 2009 43 1 139 142 10.1345/aph.1L470 19109208
    [Google Scholar]
  112. Nazarbaghi S. Amiri-Nikpour A.N. Foroughi Eghbal A. Valizadeh R. Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial. Electron. Physician 2017 9 10 5617 5622 10.19082/5617 29238506
    [Google Scholar]
  113. Bansal K. Durrani M. Methadone. StatPearls [Internet] Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  114. Pentiado Júnior J.A.M. Barbosa M.M. Kubota G.T. Martins P.N. Moreira L.I. Fernandes A.M. da Silva V.A. Júnior J.R. Yeng L.T. Teixeira M.J. Ciampi de Andrade D. METHA-NeP: Effectiveness and safety of methadone for neuropathic pain: A controlled randomized trial. Pain 2025 166 3 557 570 10.1097/j.pain.0000000000003413 39432734
    [Google Scholar]
  115. Hanna V. Senderovich H. Methadone in pain management: A systematic review. J. Pain 2021 22 3 233 245 10.1016/j.jpain.2020.04.004 32599153
    [Google Scholar]
  116. McNicol E.D. Ferguson M.C. Schumann R. Methadone for neuropathic pain in adults. Cochrane Libr. 2017 2021 1 CD012499 10.1002/14651858.CD012499.pub2 28514508
    [Google Scholar]
  117. Rosenbaum S.B. Gupta V. Patel P. Palacios J.L. Ketamine. StatPearls. Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  118. Backonja M. Arndt G. Gombar K.A. Check B. Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: A preliminary study. Pain 1994 56 1 51 57 10.1016/0304‑3959(94)90149‑X 8159441
    [Google Scholar]
  119. Huge V. Lauchart M. Magerl W. Schelling G. Beyer A. Thieme D. Azad S.C. Effects of low‐dose intranasal (S)‐ketamine in patients with neuropathic pain. Eur. J. Pain 2010 14 4 387 394 10.1016/j.ejpain.2009.08.002 19733106
    [Google Scholar]
  120. Niesters M. Martini C. Dahan A. Ketamine for chronic pain: Risks and benefits. Br. J. Clin. Pharmacol. 2014 77 2 357 367 10.1111/bcp.12094 23432384
    [Google Scholar]
  121. Maher D.P. Chen L. Mao J. Intravenous ketamine infusions for neuropathic pain management: A promising therapy in need of optimization. Anesth. Analg. 2017 124 2 661 674 10.1213/ANE.0000000000001787 28067704
    [Google Scholar]
  122. Lingamchetty T.N. Hosseini S.A. Patel P. Saadabadi A. Midazolam. StatPearls [Internet] 2023
    [Google Scholar]
  123. Shih A. Miletic V. Miletic G. Smith L.J. Midazolam administration reverses thermal hyperalgesia and prevents γ-aminobutyric acid transporter loss in a rodent model of neuropathic pain. Anesth. Analg. 2008 106 4 1296 1302 10.1213/ane.0b013e318164f1e9 18349209
    [Google Scholar]
  124. Asiedu M. Ossipov M.H. Kaila K. Price T.J. Acetazolamide and midazolam act synergistically to inhibit neuropathic pain. Pain 2010 148 2 302 308 10.1016/j.pain.2009.11.015 20007010
    [Google Scholar]
  125. Kontinen V.K. Dickenson A.H. Effects of midazolam in the spinal nerve ligation model of neuropathic pain in rats. Pain 2000 85 3 425 431 10.1016/S0304‑3959(99)00298‑5 10781915
    [Google Scholar]
  126. Yasaei R. Katta S. Patel P. Saadabadi A. Gabapentin. StatPearls [Internet] Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  127. Rosenberg J.M. Harrell C. Ristic H. Werner R.A. de Rosayro A.M. The effect of gabapentin on neuropathic pain. Clin. J. Pain 1997 13 3 251 255 10.1097/00002508‑199709000‑00011 9303258
    [Google Scholar]
  128. Bennett M.I. Simpson K.H. Gabapentin in the treatment of neuropathic pain. Palliat. Med. 2004 18 1 5 11 10.1191/0269216304pm845ra 14982201
    [Google Scholar]
  129. Davari M. Amani B. Amani B. Khanijahani A. Akbarzadeh A. Shabestan R. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: A systematic review and meta-analysis. Korean J. Pain 2020 33 1 3 12 10.3344/kjp.2020.33.1.3 31888312
    [Google Scholar]
  130. Bonnet U. Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur. Neuropsychopharmacol. 2017 27 12 1185 1215 10.1016/j.euroneuro.2017.08.430 28988943
    [Google Scholar]
  131. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). 2019 Available from:https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin
  132. Aaron L. Viswanath O. Andrew L. Pregabalin. StatPearls [Internet] Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  133. Lauria-Horner B.A. Pohl R.B. Pregabalin: A new anxiolytic. Expert Opin. Investig. Drugs 2003 12 4 663 672 10.1517/13543784.12.4.663 12665421
    [Google Scholar]
  134. Boomershine C. Pregabalin for the management of fibromyalgia syndrome. J. Pain Res. 2010 3 81 88 10.2147/JPR.S7884 21197312
    [Google Scholar]
  135. Parsons B. Fujii K. Nozawa K. Yoshiyama T. Ortiz M. Whalen E. The efficacy of pregabalin for the treatment of neuropathic pain in Japanese subjects with moderate or severe baseline pain. J. Pain Res. 2019 12 1061 1068 10.2147/JPR.S181729 30962707
    [Google Scholar]
  136. Attal N. Pharmacological treatments of neuropathic pain: The latest recommendations. Rev. Neurol. 2019 175 1-2 46 50 10.1016/j.neurol.2018.08.005 30318260
    [Google Scholar]
  137. Kopel J. Brower G.L. Effectiveness of pregabalin as a secondary treatment for neuropathic pain from postherpetic neuralgia. Proc. Bayl. Univ. Med. Cent. 2020 33 3 469 470 10.1080/08998280.2020.1767461 32675992
    [Google Scholar]
  138. Taguchi T. Nakano S. Nozawa K. Effectiveness of pregabalin treatment for neuropathic pain in patients with spine diseases: A pooled analysis of two multicenter observational studies in japan. J. Pain Res. 2021 14 757 771 10.2147/JPR.S293556 33758538
    [Google Scholar]
  139. Hägg S. Jönsson A.K. Ahlner J. Current evidence on abuse and misuse of gabapentinoids. Drug Saf. 2020 43 12 1235 1254 10.1007/s40264‑020‑00985‑6 32857333
    [Google Scholar]
  140. Marwaha R. Thour A. Amitriptyline. StatPearls [Internet] Treasure Island, FL StatPearls Publishing 2023
    [Google Scholar]
  141. Max M.B. Culnane M. Schafer S.C. Gracely R.H. Walther D.J. Smoller B. Dubner R. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987 37 4 589 596 10.1212/WNL.37.4.589 2436092
    [Google Scholar]
  142. Eija; Tiina, T.; J, N.P. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996 64 2 293 302 10.1016/0304‑3959(95)00138‑7 8740607
    [Google Scholar]
  143. Moore R.A. Derry S. Aldington D. Cole P. Wiffen P.J. Amitriptyline for neuropathic pain in adults. Cochrane Libr. 2015 2019 5 CD008242 10.1002/14651858.CD008242.pub3 26146793
    [Google Scholar]
  144. Kamble S.V. Motlekar S.A. D’souza L.L. Kudrigikar V.N. Rao S.E. Low doses of amitriptyline, pregabalin, and gabapentin are preferred for management of neuropathic pain in India: Is there a need for revisiting dosing recommendations? Korean J. Pain 2017 30 3 183 191 10.3344/kjp.2017.30.3.183 28757918
    [Google Scholar]
  145. Smith T. Nicholson R.A. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc. Health Risk Manag. 2007 3 6 833 844 18200804
    [Google Scholar]
  146. Wernicke J.F. Pritchett Y.L. D’Souza D.N. Waninger A. Tran P. Iyengar S. Raskin J. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006 67 8 1411 1420 10.1212/01.wnl.0000240225.04000.1a 17060567
    [Google Scholar]
  147. Lunn M.P.T. Hughes R.A.C. Wiffen P.J. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Libr. 2014 2015 10 CD007115 10.1002/14651858.CD007115.pub3 24385423
    [Google Scholar]
  148. Raskin J. Pritchett Y.L. Wang F. D’Souza D.N. Waninger A.L. Iyengar S. Wernicke J.F. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005 6 5 346 356 10.1111/j.1526‑4637.2005.00061.x 16266355
    [Google Scholar]
  149. Quilici S. Chancellor J. Löthgren M. Simon D. Said G. Le T.K. Garcia-Cebrian A. Monz B. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009 9 1 6 10.1186/1471‑2377‑9‑6 19208243
    [Google Scholar]
  150. Pergolizzi JV Jr Raffa RB Taylor R Jr Rodriguez G Nalamachu S Langley P A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract. 2013 13 3 239 252 10.1111/j.1533‑2500.2012.00578.x 22716295
    [Google Scholar]
  151. Oh S. Agrawal S. Sabir S. Taylor A. Dextromethorphan. StatPearls [Internet] Treasure Island, FL StatPearls Publishing 2023
    [Google Scholar]
  152. Hernandez S.C. Bertolino M. Xiao Y. Pringle K.E. Caruso F.S. Kellar K.J. Dextromethorphan and its metabolite dextrorphan block α3β4 neuronal nicotinic receptors. J. Pharmacol. Exp. Ther. 2000 293 3 962 967 10.1016/S0022‑3565(24)39320‑6 10869398
    [Google Scholar]
  153. Petrenko A.B. Yamakura T. Baba H. Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: A review. Anesth. Analg. 2003 97 4 1108 1116 10.1213/01.ANE.0000081061.12235.55 14500166
    [Google Scholar]
  154. Dulawa S.C. Janowsky D.S. Cholinergic regulation of mood: From basic and clinical studies to emerging therapeutics. Mol. Psychiatry 2019 24 5 694 709 10.1038/s41380‑018‑0219‑x 30120418
    [Google Scholar]
  155. McQuay H.J. Carroll D. Jadad A.R. Glynn C.J. Jack T. Moore A.R. Wiffen P.J. Dextromethorphan for the treatment of neuropathic pain: A double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 1994 59 1 127 133 10.1016/0304‑3959(94)90056‑6 7854793
    [Google Scholar]
  156. Carlsson K.C. Hoem N.O. Moberg E.R. Mathisen L.C. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol. Scand. 2004 48 3 328 336 10.1111/j.0001‑5172.2004.0325.x 14982566
    [Google Scholar]
  157. Shaibani A.I. Pope L.E. Thisted R. Hepner A. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for Diabetic neuropathic pain: A double-blind, placebo-controlled, multicenter study. Pain Med. 2012 13 2 243 254 10.1111/j.1526‑4637.2011.01316.x 22314263
    [Google Scholar]
  158. Wang S. Zhang L. Lim G. Sung B. Tian Y. Chou C.W. Hernstadt H. Rusanescu G. Ma Y. Mao J. A combined effect of dextromethorphan and melatonin on neuropathic pain behavior in rats. Brain Res. 2009 1288 42 49 10.1016/j.brainres.2009.06.094 19595681
    [Google Scholar]
  159. Yang P.P. Yeh G.C. Huang E.Y.K. Law P.Y. Loh H.H. Tao P.L. Effects of dextromethorphan and oxycodone on treatment of neuropathic pain in mice. J. Biomed. Sci. 2015 22 1 81 10.1186/s12929‑015‑0186‑3 26391752
    [Google Scholar]
  160. Sang C.N. Booher S. Gilron I. Parada S. Max M.B. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose-response trials. Anesthesiology 2002 96 5 1053 1061 10.1097/00000542‑200205000‑00005 11981142
    [Google Scholar]
  161. Morel V. Pickering G. Etienne M. Dupuis A. Privat A.M. Chalus M. Eschalier A. Daulhac L. Low doses of dextromethorphan have a beneficial effect in the treatment of neuropathic pain. Fundam. Clin. Pharmacol. 2014 28 6 671 680 10.1111/fcp.12076 24702319
    [Google Scholar]
  162. Badowski M.E. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: A focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother. Pharmacol. 2017 80 3 441 449 10.1007/s00280‑017‑3387‑5 28780725
    [Google Scholar]
  163. Beal J.E. Olson R. Laubenstein L. Morales J.O. Bellman P. Yangco B. Lefkowitz L. Plasse T.F. Shepard K.V. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manage. 1995 10 2 89 97 10.1016/0885‑3924(94)00117‑4 7730690
    [Google Scholar]
  164. Clermont-Gnamien S. Atlani S. Attal N. Le Mercier F. Guirimand F. Brasseur L Utilisation thérapeutique du D9- tétrahydrocannabinol (dronabinol) dans les douleurs neuropathiques réfractaires [The therapeutic use of D9- tetrahydrocannabinol (dronabinol) in refractory neuropathic pain]. Presse Med. 2002 31 39 Pt 1 1840 1845 12496714
    [Google Scholar]
  165. Iskedjian M. Bereza B. Gordon A. Piwko C. Einarson T.R. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr. Med. Res. Opin. 2007 23 1 17 24 10.1185/030079906X158066 17257464
    [Google Scholar]
  166. Narang S. Gibson D. Wasan A.D. Ross E.L. Michna E. Nedeljkovic S.S. Jamison R.N. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J. Pain 2008 9 3 254 264 10.1016/j.jpain.2007.10.018 18088560
    [Google Scholar]
  167. Rintala D.H. Fiess R.N. Tan G. Holmes S.A. Bruel B.M. Effect of dronabinol on central neuropathic pain after spinal cord injury: A pilot study. Am. J. Phys. Med. Rehabil. 2010 89 10 840 848 10.1097/PHM.0b013e3181f1c4ec 20855984
    [Google Scholar]
  168. Schimrigk S. Marziniak M. Neubauer C. Kugler E.M. Werner G. Abramov-Sommariva D. Dronabinol is a safe long-term treatment option for neuropathic pain patients. Eur. Neurol. 2017 78 5-6 320 329 10.1159/000481089 29073592
    [Google Scholar]
  169. Singh D. Saadabadi A. Venlafaxine. StatPearls Internet Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  170. Lang E. Hord A.H. Denson D. Venlafaxine hydrochloride (EffexorTM) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Pain 1996 68 1 151 155 10.1016/S0304‑3959(96)03223‑X 9252010
    [Google Scholar]
  171. Yücel A. Özyalçın S. Talu G.K. Kiziltan E. Yücel B. Andersen O.K. Arendt-Nielsen L. Disci R. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: A double blind, placebo controlled study. Eur. J. Pain 2005 9 4 407 416 10.1016/j.ejpain.2004.09.009 15979021
    [Google Scholar]
  172. Sumpton J.E. Moulin D.E. Treatment of neuropathic pain with venlafaxine. Ann. Pharmacother. 2001 35 5 557 559 10.1345/aph.10206 11346061
    [Google Scholar]
  173. Tasmuth T. Härtel B. Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur. J. Pain 2002 6 1 17 24 10.1053/eujp.2001.0266 11888224
    [Google Scholar]
  174. Nazarian S. Akhondi H. Minocycline. StatPearls [Internet] Treasure Island, FL StatPearls Publishing 2023
    [Google Scholar]
  175. Garner S.E. Eady A. Bennett C. Newton J.N. Thomas K. Popescu C.M. Minocycline for acne vulgaris: Efficacy and safety. Cochrane Libr. 2012 2013 7 CD002086 10.1002/14651858.CD002086.pub2 22895927
    [Google Scholar]
  176. Padi S.S.V. Kulkarni S.K. Minocycline prevents the development of neuropathic pain, but not acute pain: Possible anti-inflammatory and antioxidant mechanisms. Eur. J. Pharmacol. 2008 601 1-3 79 87 10.1016/j.ejphar.2008.10.018 18952075
    [Google Scholar]
  177. Mei X.P. Xu H. Xie C. Ren J. Zhou Y. Zhang H. Xu L.X. Post-injury administration of minocycline: An effective treatment for nerve-injury induced neuropathic pain. Neurosci. Res. 2011 70 3 305 312 10.1016/j.neures.2011.03.012 21515316
    [Google Scholar]
  178. Pabreja K. Dua K. Sharma S. Padi S.S.V. Kulkarni S.K. Minocycline attenuates the development of diabetic neuropathic pain: Possible anti-inflammatory and anti-oxidant mechanisms. Eur. J. Pharmacol. 2011 661 1-3 15 21 10.1016/j.ejphar.2011.04.014 21536024
    [Google Scholar]
  179. Dhesi M. Maldonado K.A. Patel P. Maani C.V. Tramadol. StatPearls [Internet] Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  180. Bravo L. Mico J.A. Berrocoso E. Discovery and development of tramadol for the treatment of pain. Expert Opin. Drug Discov. 2017 12 12 1281 1291 10.1080/17460441.2017.1377697 28920461
    [Google Scholar]
  181. Finnerup N.B. Attal N. Haroutounian S. McNicol E. Baron R. Dworkin R.H. Gilron I. Haanpää M. Hansson P. Jensen T.S. Kamerman P.R. Lund K. Moore A. Raja S.N. Rice A.S.C. Rowbotham M. Sena E. Siddall P. Smith B.H. Wallace M. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015 14 2 162 173 10.1016/S1474‑4422(14)70251‑0 25575710
    [Google Scholar]
  182. Pickering G. Pereira B. Morel V. Corriger A. Giron F. Marcaillou F. Bidar-Beauvallot A. Chandeze E. Lambert C. Bernard L. Delage N. Ketamine and magnesium for refractory neuropathic pain. Anesthesiology 2020 133 1 154 164 10.1097/ALN.0000000000003345 32384291
    [Google Scholar]
  183. Aiyer R. Mehta N. Gungor S. Gulati A. A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice. Clin. J. Pain 2018 34 5 450 467 10.1097/AJP.0000000000000547 28877137
    [Google Scholar]
  184. Malerba M. Ragnoli B. Ambroxol in the 21st century: Pharmacological and clinical update. Expert Opin. Drug Metab. Toxicol. 2008 4 8 1119 1129 10.1517/17425255.4.8.1119 18680446
    [Google Scholar]
  185. Russo M.A. Baron R. Dickenson A.H. Kern K.U. Santarelli D.M. Ambroxol for neuropathic pain: Hiding in plain sight? Pain 2023 164 1 3 13 10.1097/j.pain.0000000000002693 35580314
    [Google Scholar]
  186. Salat K. Gryzlo B. Kulig K. Experimental drugs for neuropathic pain. Curr. Neuropharmacol. 2018 16 8 1193 1209 10.2174/1570159X16666180510151241 29745335
    [Google Scholar]
  187. Gaida W. Klinder K. Arndt K. Weiser T. Ambroxol, a Nav1.8-preferring Na+ channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology 2005 49 8 1220 1227 10.1016/j.neuropharm.2005.08.004 16182323
    [Google Scholar]
  188. Furgała A. Fijałkowski Ł. Nowaczyk A. Sałat R. Sałat K. Time-shifted co-administration of sub-analgesic doses of ambroxol and pregabalin attenuates oxaliplatin-induced cold allodynia in mice. Biomed. Pharmacother. 2018 106 930 940 10.1016/j.biopha.2018.07.039 30119265
    [Google Scholar]
  189. Hama A.T. Plum A.W. Sagen J. Antinociceptive effect of ambroxol in rats with neuropathic spinal cord injury pain. Pharmacol. Biochem. Behav. 2010 97 2 249 255 10.1016/j.pbb.2010.08.006 20732348
    [Google Scholar]
  190. Kern K.U. Weiser T. Topical ambroxol for the treatment of neuropathic pain. Schmerz 2015 29 S3 89 96 10.1007/s00482‑015‑0060‑y 26589711
    [Google Scholar]
  191. Kern K.U. Schwickert-Nieswandt M. Maihöfner C. Gaul C. Topical ambroxol 20% for the treatment of classical trigeminal neuralgia – A new option? initial clinical case observations. Headache 2019 59 3 418 429 10.1111/head.13475 30653673
    [Google Scholar]
  192. McCarberg B.H. Barkin R.L. The future of cannabinoids as analgesic agents: A pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am. J. Ther. 2007 14 5 475 483 10.1097/MJT.0b013e3180a5e581 17890938
    [Google Scholar]
  193. Atakan Z. Cannabis, A complex plant: different compounds and different effects on individuals. Ther. Adv. Psychopharmacol. 2012 2 6 241 254 10.1177/2045125312457586 23983983
    [Google Scholar]
  194. Hampson A.J. Grimaldi M. Axelrod J. Wink D. Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 1998 95 14 8268 8273 10.1073/pnas.95.14.8268 9653176
    [Google Scholar]
  195. Rock E.M. Bolognini D. Limebeer C.L. Cascio M.G. Anavi-Goffer S. Fletcher P.J. Mechoulam R. Pertwee R.G. Parker L.A. Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT 1A somatodendritic autoreceptors in the dorsal raphe nucleus. Br. J. Pharmacol. 2012 165 8 2620 2634 10.1111/j.1476‑5381.2011.01621.x 21827451
    [Google Scholar]
  196. Baker D. Pryce G. Croxford J.L. Brown P. Pertwee R.G. Huffman J.W. Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000 404 6773 84 87 10.1038/35003583 10716447
    [Google Scholar]
  197. Britch S.C. Babalonis S. Walsh S.L. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology 2021 238 1 9 28 10.1007/s00213‑020‑05712‑8 33221931
    [Google Scholar]
  198. Almogi-Hazan O. Or R. Cannabis, the endocannabinoid system and immunity—the journey from the bedside to the bench and back. Int. J. Mol. Sci. 2020 21 12 4448 10.3390/ijms21124448 32585801
    [Google Scholar]
  199. Laprairie R.B. Bagher A.M. Kelly M.E.M. Denovan-Wright E.M. Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor. Br. J. Pharmacol. 2015 172 20 4790 4805 10.1111/bph.13250 26218440
    [Google Scholar]
  200. Onaivi E.S. Ishiguro H. Gong J.P. Patel S. Perchuk A. Meozzi P.A. Myers L. Mora Z. Tagliaferro P. Gardner E. Brusco A. Akinshola B. Liu Q.R. Hope B. Iwasaki S. Arinami T. Teasenfitz L. Uhl G.R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N. Y. Acad. Sci. 2006 1074 1 514 536 10.1196/annals.1369.052 17105950
    [Google Scholar]
  201. Petzke F. Tölle T. Fitzcharles M.A. Häuser W. Cannabis-based medicines and medical cannabis for chronic neuropathic pain. CNS Drugs 2022 36 1 31 44 10.1007/s40263‑021‑00879‑w 34802112
    [Google Scholar]
  202. Baron-Flores V. Diaz-Ruiz A. Manzanares J. Rios C. Burelo M. Jardon-Guadarrama G. Martínez-Cárdenas M.Á. Mata-Bermudez A. Cannabidiol attenuates hypersensitivity and oxidative stress after traumatic spinal cord injury in rats. Neurosci. Lett. 2022 788 136855 10.1016/j.neulet.2022.136855 36028005
    [Google Scholar]
  203. dos Santos R. Veras F. Netto G. Elisei L. Sorgi C. Faccioli L. Galdino G. Cannabidiol prevents chemotherapy-induced neuropathic pain by modulating spinal TLR4 via endocannabinoid system activation. J. Pharm. Pharmacol. 2023 75 5 655 665 10.1093/jpp/rgad023 36946366
    [Google Scholar]
  204. Eeswara A. Pacheco-Spiewak A. Jergova S. Sagen J. Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model. PLoS One 2023 18 3 e0282920 10.1371/journal.pone.0282920 36913400
    [Google Scholar]
  205. Haleem R. Wright R. A Scoping Review on Clinical Trials of Pain Reduction With Cannabis Administration in Adults. J. Clin. Med. Res. 2020 12 6 344 351 10.14740/jocmr4210 32587650
    [Google Scholar]
  206. Pramhas S. Thalhammer T. Terner S. Pickelsberger D. Gleiss A. Sator S. Kress H.G. Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. Lancet Reg. Health Eur. 2023 35 100777 10.1016/j.lanepe.2023.100777 38033459
    [Google Scholar]
  207. Sainsbury B. Bloxham J. Pour M.H. Padilla M. Enciso R. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: A systematic review with meta-analysis. J. Dent. Anesth. Pain Med. 2021 21 6 479 506 10.17245/jdapm.2021.21.6.479 34909469
    [Google Scholar]
  208. Filippini G. Minozzi S. Borrelli F. Cinquini M. Dwan K. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Libr. 2022 5 5 CD013444 10.1002/14651858.CD013444.pub2 35510826
    [Google Scholar]
  209. Medical cannabis (and cannabis oils). 2025 Available from:https://www.nhs.uk/conditions/medical-cannabis
  210. Arout C.A. Haney M. Herrmann E.S. Bedi G. Cooper Z.D. A placebo‐controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. Br. J. Clin. Pharmacol. 2022 88 1 347 355 10.1111/bcp.14973 34223660
    [Google Scholar]
  211. Chesney E. Oliver D. Green A. Sovi S. Wilson J. Englund A. Freeman T.P. McGuire P. Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 2020 45 11 1799 1806 10.1038/s41386‑020‑0667‑2 32268347
    [Google Scholar]
  212. Huestis M.A. Solimini R. Pichini S. Pacifici R. Carlier J. Busardò F.P. Cannabidiol adverse effects and toxicity. Curr. Neuropharmacol. 2019 17 10 974 989 10.2174/1570159X17666190603171901 31161980
    [Google Scholar]
  213. Lucas C.J. Galettis P. Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br. J. Clin. Pharmacol. 2018 84 11 2477 2482 10.1111/bcp.13710 30001569
    [Google Scholar]
  214. Bakare A.O. Owoyele B.V. Antinociceptive and neuroprotective effects of bromelain in chronic constriction injury-induced neuropathic pain in Wistar rats. Korean J. Pain 2020 33 1 13 22 10.3344/kjp.2020.33.1.13 31888313
    [Google Scholar]
  215. Bakare A.O. Owoyele B.V. Bromelain reversed electrolyte imbalance in the chronically constricted sciatic nerve of Wistar rats. Naunyn Schmiedebergs Arch. Pharmacol. 2020 393 3 457 467 10.1007/s00210‑019‑01744‑w 31655851
    [Google Scholar]
  216. Bakare A.O. Owoyele B.V. Bromelain reduced pro-inflammatory mediators as a common pathway that mediate antinociceptive and anti-anxiety effects in sciatic nerve ligated Wistar rats. Sci. Rep. 2021 11 1 289 10.1038/s41598‑020‑79421‑9 33432004
    [Google Scholar]
  217. Desideri I. Francolini G. Becherini C. Terziani F. Delli Paoli C. Olmetto E. Loi M. Perna M. Meattini I. Scotti V. Greto D. Bonomo P. Sulprizio S. Livi L. Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary issue (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospective study. Med. Oncol. 2017 34 3 46 10.1007/s12032‑017‑0907‑4 28205185
    [Google Scholar]
  218. Carpentieri A. Díaz de Barboza G. Areco V. Peralta López M. Tolosa de Talamoni N. New perspectives in melatonin uses. Pharmacol. Res. 2012 65 4 437 444 10.1016/j.phrs.2012.01.003 22311380
    [Google Scholar]
  219. Acuña Castroviejo D. López L.C. Escames G. López A. García J.A. Reiter R.J. Melatonin-mitochondria interplay in health and disease. Curr. Top. Med. Chem. 2011 11 2 221 240 10.2174/156802611794863517 21244359
    [Google Scholar]
  220. Reiter R.J. Mayo J.C. Tan D.X. Sainz R.M. Alatorre-Jimenez M. Qin L. Melatonin as an antioxidant: Under promises but over delivers. J. Pineal Res. 2016 61 3 253 278 10.1111/jpi.12360 27500468
    [Google Scholar]
  221. López A. García J.A. Escames G. Venegas C. Ortiz F. López L.C. Acuña-Castroviejo D. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J. Pineal Res. 2009 46 2 188 198 10.1111/j.1600‑079X.2008.00647.x 19054298
    [Google Scholar]
  222. Legros C. Chesneau D. Boutin J.A. Barc C. Malpaux B. Melatonin from cerebrospinal fluid but not from blood reaches sheep cerebral tissues under physiological conditions. J. Neuroendocrinol. 2014 26 3 151 163 10.1111/jne.12134 24460899
    [Google Scholar]
  223. Ambriz-Tututi M. Rocha-González H.I. Cruz S.L. Granados-Soto V. Melatonin: A hormone that modulates pain. Life Sci. 2009 84 15-16 489 498 10.1016/j.lfs.2009.01.024 19223003
    [Google Scholar]
  224. Posa L. De Gregorio D. Gobbi G. Comai S. Targeting melatonin MT2 receptors: A novel pharmacological avenue for inflammatory and neuropathic pain. Curr. Med. Chem. 2018 25 32 3866 3882 10.2174/0929867324666170209104926 28183259
    [Google Scholar]
  225. Al-Omary F.A. Melatonin: Comprehensive profile. Profiles Drug Subst. Excip. Relat. Methodol. 2013 38 159 226 10.1016/B978‑0‑12‑407691‑4.00005‑8 23668405
    [Google Scholar]
  226. Kuthati Y. Lin S.H. Chen I.J. Wong C.S. Melatonin and their analogs as a potential use in the management of Neuropathic pain. J. Formos. Med. Assoc. 2019 118 8 1177 1186 10.1016/j.jfma.2018.09.017 30316678
    [Google Scholar]
  227. Xie S. Fan W. He H. Huang F. Role of melatonin in the regulation of pain. J. Pain Res. 2020 13 331 343 10.2147/JPR.S228577 32104055
    [Google Scholar]
  228. Borsani E. Buffoli B. Bonazza V. Reiter R. Rezzani R. Rodella L. Single administration of melatonin modulates the nitroxidergic system at the peripheral level and reduces thermal nociceptive hypersensitivity in neuropathic rats. Int. J. Mol. Sci. 2017 18 10 2143 10.3390/ijms18102143 29036889
    [Google Scholar]
  229. Huang C.T. Chen S.H. Chang C.F. Lin S.C. Lue J.H. Tsai Y.J. Melatonin reduces neuropathic pain behavior and glial activation through MT2 melatonin receptor modulation in a rat model of lysophosphatidylcholine-induced demyelination neuropathy. Neurochem. Int. 2020 140 104827 10.1016/j.neuint.2020.104827 32853748
    [Google Scholar]
  230. Fakhri S. Kiani A. Jalili C. Abbaszadeh F. Piri S. Farzaei M.H. Rastegari-Pouyani M. Mohammadi-Noori E. Khan H. Intrathecal administration of melatonin ameliorates the neuroinflammation- mediated sensory and motor dysfunction in a rat model of compression spinal cord injury. Curr. Mol. Pharmacol. 2021 14 4 646 657 10.2174/1874467213666201230101811 33380311
    [Google Scholar]
  231. Marchesi N. Govoni S. Allegri M. Non‐drug pain relievers active on non‐opioid pain mechanisms. Pain Pract. 2022 22 2 255 275 10.1111/papr.13073 34498362
    [Google Scholar]
  232. Horst A. de Souza J.A. Santos M.C.Q. Riffel A.P.K. Kolberg C. Partata W.A. Effects of N-acetylcysteine on spinal cord oxidative stress biomarkers in rats with neuropathic pain. Braz. J. Med. Biol. Res. 2017 50 12 e6533 10.1590/1414‑431x20176533 29069230
    [Google Scholar]
  233. Horst A. Kolberg C. Moraes M.S. Riffel A.P.K. Finamor I.A. Belló-Klein A. Pavanato M.A. Partata W.A. Effect of N-acetylcysteine on the spinal-cord glutathione system and nitric-oxide metabolites in rats with neuropathic pain. Neurosci. Lett. 2014 569 163 168 10.1016/j.neulet.2014.03.063 24704379
    [Google Scholar]
  234. Bernabucci M. Notartomaso S. Zappulla C. Fazio F. Cannella M. Motolese M. Battaglia G. Bruno V. Gradini R. Nicoletti F. N-Acetyl-cysteine causes analgesia by reinforcing the endogenous activation of type-2 metabotropic glutamate receptors. Mol. Pain 2012 8 1744-8069 8-77 10.1186/1744‑8069‑8‑77 23088864
    [Google Scholar]
  235. Özgül C. Nazıroğlu M. TRPM2 channel protective properties of N-acetylcysteine on cytosolic glutathione depletion dependent oxidative stress and Ca2+ influx in rat dorsal root ganglion. Physiol. Behav. 2012 106 2 122 128 10.1016/j.physbeh.2012.01.014 22300897
    [Google Scholar]
  236. Sözbir E. Nazıroğlu M. Diabetes enhances oxidative stress-induced TRPM2 channel activity and its control by N-acetylcysteine in rat dorsal root ganglion and brain. Metab. Brain Dis. 2016 31 2 385 393 10.1007/s11011‑015‑9769‑7 26612073
    [Google Scholar]
  237. Notartomaso S. Scarselli P. Mascio G. Liberatore F. Mazzon E. Mammana S. Gugliandolo A. Cruccu G. Bruno V. Nicoletti F. Battaglia G. N-Acetylcysteine causes analgesia in a mouse model of painful diabetic neuropathy. Mol. Pain 2020 16 1744806920904292 10.1177/1744806920904292 32009537
    [Google Scholar]
  238. Li J. Xu L. Deng X. Jiang C. Pan C. Chen L. Han Y. Dai W. Hu L. Zhang G. Cheng Z. Liu W. N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. Pain 2016 157 8 1711 1723 10.1097/j.pain.0000000000000575 27075430
    [Google Scholar]
  239. Heidari N. Sajedi F. Mohammadi Y. Mirjalili M. Mehrpooya M. Ameliorative effects of n-acetylcysteine as adjunct therapy on symptoms of painful diabetic neuropathy. J. Pain Res. 2019 12 3147 3159 10.2147/JPR.S228255 31819599
    [Google Scholar]
  240. Mohiuddin M. Pivetta B. Gilron I. Khan J.S. Efficacy and safety of N-Acetylcysteine for the management of chronic pain in adults: A systematic review and meta-analysis. Pain Med. 2021 22 12 2896 2907 10.1093/pm/pnab042 33560443
    [Google Scholar]
  241. Raghu G. Berk M. Campochiaro P.A. Jaeschke H. Marenzi G. Richeldi L. Wen F-Q. Nicoletti F. Calverley P.M.A. The multifaceted therapeutic role of N-Acetylcysteine (NAC) in disorders characterized by oxidative stress. Curr. Neuropharmacol. 2021 19 8 1202 1224 10.2174/18756190MTEycODQ8w 33380301
    [Google Scholar]
  242. Shinu P. Morsy M.A. Nair A.B. Mouslem A.K.A. Venugopala K.N. Goyal M. Bansal M. Jacob S. Deb P.K. Novel therapies for the treatment of neuropathic pain: Potential and pitfalls. J. Clin. Med. 2022 11 11 3002 10.3390/jcm11113002 35683390
    [Google Scholar]
  243. Campbell T.S. Johnson J.A. Zernicke K.A. Gate Control Theory of Pain. Encyclopedia of Behavioral Medicine. Gellman M.D. Turner J.R. Springer 2013 832 834 10.1007/978‑1‑4419‑1005‑9_1134
    [Google Scholar]
  244. Wolter T. Spinal cord stimulation for neuropathic pain: Current perspectives. J. Pain Res. 2014 7 651 663 10.2147/JPR.S37589 25429237
    [Google Scholar]
  245. Caylor J. Reddy R. Yin S. Cui C. Huang M. Huang C. Rao R. Baker D.G. Simmons A. Souza D. Narouze S. Vallejo R. Lerman I. Spinal cord stimulation in chronic pain: Evidence and theory for mechanisms of action. Bioelectron. Med. 2019 5 1 12 10.1186/s42234‑019‑0023‑1 31435499
    [Google Scholar]
  246. El-Naggar A.O. Reis C.L. Hatheway J.A. Schmidt T.E. Pico T.C. Sanapati M.R. Abd-Elsayed A. Patel A.S. Calodney A. Johanek L. Tan Y. McCammon S. Using lower amplitudes to maintain effective high dose Spinal Cord Stimulation therapy (SCS Dosing Pilot Study). Neuromodulation 2021 24 3 532 539 10.1111/ner.13258 32946181
    [Google Scholar]
  247. Galan V. Scowcroft J. Chang P. Li S. Staats P. Subbaroyan J. Caraway D. Ten kHz spinal cord stimulation for the treatment of chronic peripheral polyneuropathy: 12‐Month results from prospective open‐label pilot study. Pain Pract. 2021 21 8 898 906 10.1111/papr.13059 34251751
    [Google Scholar]
  248. Guan Y. Spinal cord stimulation: Neurophysiological and neurochemical mechanisms of action. Curr. Pain Headache Rep. 2012 16 3 217 225 10.1007/s11916‑012‑0260‑4 22399391
    [Google Scholar]
  249. Shechter R. Yang F. Xu Q. Cheong Y.K. He S.Q. Sdrulla A. Carteret A.F. Wacnik P.W. Dong X. Meyer R.A. Raja S.N. Guan Y. Conventional and kilohertz-frequency spinal cord stimulation produces intensity- and frequency-dependent inhibition of mechanical hypersensitivity in a rat model of neuropathic pain. Anesthesiology 2013 119 2 422 432 10.1097/ALN.0b013e31829bd9e2 23880991
    [Google Scholar]
  250. Deer T.R. Krames E. Mekhail N. Pope J. Leong M. Stanton-Hicks M. Golovac S. Kapural L. Alo K. Anderson J. Foreman R.D. Caraway D. Narouze S. Linderoth B. Buvanendran A. Feler C. Poree L. Lynch P. McJunkin T. Swing T. Staats P. Liem L. Williams K. The appropriate use of neurostimulation: New and evolving neurostimulation therapies and applicable treatment for chronic pain and selected disease states. Neuromodulation 2014 17 6 599 615 Neuromodulation Appropriateness Consensus Committee. 10.1111/ner.12204 25112892
    [Google Scholar]
  251. Kumar K. Taylor R.S. Jacques L. Eldabe S. Meglio M. Molet J. Thomson S. O’Callaghan J. Eisenberg E. Milbouw G. Buchser E. Fortini G. Richardson J. North R.B. The effects of spinal cord stimulation in neuropathic pain are sustained: A 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. Neurosurgery 2008 63 4 762 770 10.1227/01.NEU.0000325731.46702.D9 18981888
    [Google Scholar]
  252. Slangen R. Schaper N.C. Faber C.G. Joosten E.A. Dirksen C.D. van Dongen R.T. Kessels A.G. van Kleef M. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: A prospective two-center randomized controlled trial. Diabetes Care 2014 37 11 3016 3024 10.2337/dc14‑0684 25216508
    [Google Scholar]
  253. Cruccu G. Aziz T.Z. Garcia-Larrea L. Hansson P. Jensen T.S. Lefaucheur J.P. Simpson B.A. Taylor R.S. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur. J. Neurol. 2007 14 9 952 970 10.1111/j.1468‑1331.2007.01916.x 17718686
    [Google Scholar]
  254. Pang D. Current experience of spinal neuromodulation in chronic pain: Is there a role in children and young people? Eur. J. Paediatr. Neurol. 2017 21 1 56 66 10.1016/j.ejpn.2016.07.001 27658771
    [Google Scholar]
  255. Kunnumpurath S. Srinivasagopalan R. Vadivelu N. Spinal cord stimulation: Principles of past, present and future practice: A review. J. Clin. Monit. Comput. 2009 23 5 333 339 10.1007/s10877‑009‑9201‑0 19728120
    [Google Scholar]
  256. Bendersky D. Yampolsky C. Is spinal cord stimulation safe? A review of its complications. World Neurosurg. 2014 82 6 1359 1368 10.1016/j.wneu.2013.06.012 23851231
    [Google Scholar]
  257. Zan E. Kurt K.N. Yousem D.M. Christo P.J. Spinal cord stimulators: Typical positioning and postsurgical complications. AJR Am. J. Roentgenol. 2011 196 2 437 445 10.2214/AJR.10.4789 21257898
    [Google Scholar]
  258. Henson J.V. Varhabhatla N.C. Bebic Z. Kaye A.D. Yong R.J. Urman R.D. Merkow J.S. Spinal cord stimulation for painful Diabetic peripheral neuropathy: A systematic review. Pain Ther. 2021 10 2 895 908 10.1007/s40122‑021‑00282‑9 34244979
    [Google Scholar]
  259. Meuwissen K.P.V. van der Toorn A. Gu J.W. Zhang T.C. Dijkhuizen R.M. Joosten E.A.J. Active recharge burst and tonic spinal cord stimulation engage different supraspinal mechanisms: A functional magnetic resonance imaging study in peripherally injured chronic neuropathic rats. Pain Pract. 2020 20 5 510 521 10.1111/papr.12879 32124540
    [Google Scholar]
  260. Joosten E.A. Franken G. Spinal cord stimulation in chronic neuropathic pain: Mechanisms of action, new locations, new paradigms. Pain 2020 161 1 S104 S113 10.1097/j.pain.0000000000001854 33090743
    [Google Scholar]
  261. Dombovy-Johnson M.L. Hunt C.L. Morrow M.M. Lamer T.J. Pittelkow T.P. Current evidence lacking to guide clinical practice for spinal cord stimulation in the treatment of neuropathic pain in spinal cord injury: A review of the literature and a proposal for future study. Pain Pract. 2020 20 3 325 335 10.1111/papr.12855 31691496
    [Google Scholar]
  262. Kapural L. Yu C. Doust M.W. Gliner B.E. Vallejo R. Sitzman B.T. Amirdelfan K. Morgan D.M. Brown L.L. Yearwood T.L. Bundschu R. Burton A.W. Yang T. Benyamin R. Burgher A.H. Novel 10-kHz High-frequency Therapy (HF10 Therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain. Anesthesiology 2015 123 4 851 860 10.1097/ALN.0000000000000774 26218762
    [Google Scholar]
  263. Bhatia A. Flamer D. Shah P.S. Perineural steroids for trauma and compression-related peripheral neuropathic pain: A systematic review and meta-analysis. Can. J. Anaesth. 2015 62 6 650 662 10.1007/s12630‑015‑0356‑5 25744141
    [Google Scholar]
  264. Couch B. Hayward D. Baum G. Sakthiyendran N.A. Harder J. Hernandez E.J. MacKay B. A systematic review of steroid use in peripheral nerve pathologies and treatment. Front. Neurol. 2024 15 1434429 10.3389/fneur.2024.1434429 39286807
    [Google Scholar]
  265. Chou R. Hashimoto R. Friedly J. Fu R. Bougatsos C. Dana T. Sullivan S.D. Jarvik J. Epidural corticosteroid injections for radiculopathy and spinal stenosis: A systematic review and meta-analysis. Ann. Intern. Med. 2015 163 5 373 381 10.7326/M15‑0934 26302454
    [Google Scholar]
  266. Colloca L. Ludman T. Bouhassira D. Baron R. Dickenson A.H. Yarnitsky D. Freeman R. Truini A. Attal N. Finnerup N.B. Eccleston C. Kalso E. Bennett D.L. Dworkin R.H. Raja S.N. Neuropathic pain. Nat. Rev. Dis. Primers 2017 3 1 17002 10.1038/nrdp.2017.2 28205574
    [Google Scholar]
  267. Krieg T.D. Salinas F.S. Narayana S. Fox P.T. Mogul D.J. Computational and experimental analysis of TMS-induced electric field vectors critical to neuronal activation. J. Neural Eng. 2015 12 4 046014 10.1088/1741‑2560/12/4/046014 26052136
    [Google Scholar]
  268. Klomjai W. Katz R. Lackmy-Vallée A. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). Ann. Phys. Rehabil. Med. 2015 58 4 208 213 10.1016/j.rehab.2015.05.005 26319963
    [Google Scholar]
  269. Enticott P.G. Barlow K. Guastella A.J. Licari M.K. Rogasch N.C. Middeldorp C.M. Clark S.R. Vallence A.M. Boulton K.A. Hickie I.B. Whitehouse A.J.O. Galletly C. Alvares G.A. Fujiyama H. Heussler H. Craig J.M. Kirkovski M. Mills N.T. Rinehart N.J. Donaldson P.H. Ford T.C. Caeyenberghs K. Albein-Urios N. Bekkali S. Fitzgerald P.B. Repetitive transcranial magnetic stimulation (rTMS) in autism spectrum disorder: Protocol for a multicentre randomised controlled clinical trial. BMJ Open 2021 11 7 e046830 10.1136/bmjopen‑2020‑046830 34233985
    [Google Scholar]
  270. Lefaucheur J.P. Aleman A. Baeken C. Benninger D.H. Brunelin J. Di Lazzaro V. Filipović S.R. Grefkes C. Hasan A. Hummel F.C. Jääskeläinen S.K. Langguth B. Leocani L. Londero A. Nardone R. Nguyen J.P. Nyffeler T. Oliveira-Maia A.J. Oliviero A. Padberg F. Palm U. Paulus W. Poulet E. Quartarone A. Rachid F. Rektorová I. Rossi S. Sahlsten H. Schecklmann M. Szekely D. Ziemann U. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). Clin. Neurophysiol. 2020 131 2 474 528 10.1016/j.clinph.2019.11.002 31901449
    [Google Scholar]
  271. Strafella A.P. Paus T. Fraraccio M. Dagher A. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain 2003 126 12 2609 2615 10.1093/brain/awg268 12937078
    [Google Scholar]
  272. Turco C.V. Nelson A.J. Transcranial magnetic stimulation to assess exercise-induced neuroplasticity. Frontiers in Neuroergonomics 2021 2 679033 10.3389/fnrgo.2021.679033 38235229
    [Google Scholar]
  273. Quesada C. Pommier B. Fauchon C. Bradley C. Créac’h C. Murat M. Vassal F. Peyron R. New procedure of high-frequency repetitive transcranial magnetic stimulation for central neuropathic pain: A placebo-controlled randomized crossover study. Pain 2020 161 4 718 728 10.1097/j.pain.0000000000001760 31764387
    [Google Scholar]
  274. D’Ostilio K. Magis D. Invasive and non-invasive electrical pericranial nerve stimulation for the treatment of chronic primary headaches. Curr. Pain Headache Rep. 2016 20 11 61 10.1007/s11916‑016‑0589‑1 27678260
    [Google Scholar]
  275. Lefaucheur J.P. Cortical neurostimulation for neuropathic pain. Pain 2016 157 Suppl. 1 S81 S89 10.1097/j.pain.0000000000000401 26785160
    [Google Scholar]
  276. Keifer O.P. Riley J.P. Boulis N.M. Deep brain stimulation for chronic pain: Intracranial targets, clinical outcomes, and trial design considerations. Neurosurg. Clin. N. Am. 2014 25 4 671 692 10.1016/j.nec.2014.07.009 25240656
    [Google Scholar]
  277. Deep brain stimulation for refractory chronic pain syndromes (excluding headache). 2011 NICE Available from:www.nice.org.uk/guidance/ipg382
    [Google Scholar]
  278. Tan T. Barry P. Reken S. Baker M. Pharmacological management of neuropathic pain in non-specialist settings: Summary of NICE guidance. BMJ 2010 240 mar24 1 c1079 Guideline Development Group. 10.1136/bmj.c1079 20335333
    [Google Scholar]
  279. Rossi M. DeCarolis G. Liberatoscioli G. Iemma D. Nosella P. Nardi L.F. A novel mini-invasive approach to the treatment of neuropathic pain: The PENS study. Pain Physician 2016 19 1 E121 E128 26752480
    [Google Scholar]
  280. de Sire A. Ammendolia A. Lippi L. Farì G. Cisari C. Invernizzi M. Percutaneous electrical nerve stimulation (Pens) as a rehabilitation approach for reducing mixed chronic pain in patients with musculoskeletal disorders. Appl. Sci. 2021 11 9 4257 10.3390/app11094257
    [Google Scholar]
  281. Gavronsky S. Koeniger-Donohue R. Steller J. Hawkins J.W. Postoperative pain: Acupuncture versus percutaneous electrical nerve stimulation. Pain Manag. Nurs. 2012 13 3 150 156 10.1016/j.pmn.2009.08.001 22929602
    [Google Scholar]
  282. Hernandez J.V.L. Calvo-Lobo C. Zugasti A.M.P. Fernandez-Carnero J. Beltran Alacreu H. Effectiveness of dry needling with percutaneous electrical nerve stimulation of high frequency versus low frequency in patients with myofascial neck pain. Pain Physician 2021 24 2 135 143 10.36076/ppj.2021.24.135‑143 33740346
    [Google Scholar]
  283. Hamza M.A. White P.F. Craig W.F. Ghoname E.S. Ahmed H.E. Proctor T.J. Noe C.E. Vakharia A.S. Gajraj N. Percutaneous electrical nerve stimulation: A novel analgesic therapy for diabetic neuropathic pain. Diabetes Care 2000 23 3 365 370 10.2337/diacare.23.3.365 10868867
    [Google Scholar]
  284. Gozani S.N. Remote analgesic effects of conventional transcutaneous electrical nerve stimulation: A scientific and clinical review with a focus on chronic pain. J. Pain Res. 2019 12 3185 3201 10.2147/JPR.S226600 31819603
    [Google Scholar]
  285. Verrills P. Vivian D. Mitchell B. Barnard A. Peripheral nerve field stimulation for chronic pain: 100 cases and review of the literature. Pain Med. 2011 12 9 1395 1405 10.1111/j.1526‑4637.2011.01201.x 21812906
    [Google Scholar]
  286. Eldabe S. Copley S. Gulve A. Baranidharan G. Bretherton B. Kansal A. Madzinga G. Brookes M. Thomson S. Duarte R.V. A prospective long-term follow-up of dorsal root ganglion stimulation for the management of chronic intractable pain. Pain 2022 163 4 702 710 10.1097/j.pain.0000000000002405 35302973
    [Google Scholar]
  287. Liem L. Russo M. Huygen F.J.P.M. Van Buyten J.P. Smet I. Verrills P. Cousins M. Brooker C. Levy R. Deer T. Kramer J. One-year outcomes of spinal cord stimulation of the dorsal root ganglion in the treatment of chronic neuropathic pain. Neuromodulation 2015 18 1 41 49 10.1111/ner.12228 25145467
    [Google Scholar]
  288. Law L. Rayi A. Hendrix J.M. Derian A. Cryoanalgesia. StatPearls [Internet] Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  289. Yoon J.H.E. Grechushkin V. Chaudhry A. Bhattacharji P. Durkin B. Moore W. Cryoneurolysis in patients with refractory chronic peripheral neuropathic pain. J. Vasc. Interv. Radiol. 2016 27 2 239 243 10.1016/j.jvir.2015.11.027 26710969
    [Google Scholar]
  290. McLean B.C. Nguyen C.D. Newman D.P. Cryoablation of the infrapatellar branch of the saphenous nerve identified by non-invasive peripheral nerve stimulator for the treatment of non-surgical anterior knee pain: A case series and review of the literature. Cureus 2020 12 6 e8747 10.7759/cureus.8747 32714685
    [Google Scholar]
  291. Li F. Ni J. Li H. Li Y. Guo Z. Hao L. Li Y. Tang Y. Guo Y. Zhang D. He L. Wang Y. Meng Y. Low-temperature plasma radiofrequency ablation in phantom limb pain: A case report. Brain Circ. 2018 4 2 62 64 10.4103/bc.bc_7_17 30276338
    [Google Scholar]
  292. Varshney V. Osborn J. Chaturvedi R. Shah V. Chakravarthy K. Advances in the interventional management of neuropathic pain. Ann. Transl. Med. 2021 9 2 187 10.21037/atm‑20‑6190 33569489
    [Google Scholar]
  293. Iyer S.M. Vesuna S. Ramakrishnan C. Huynh K. Young S. Berndt A. Lee S.Y. Gorini C.J. Deisseroth K. Delp S.L. Optogenetic and chemogenetic strategies for sustained inhibition of pain. Sci. Rep. 2016 6 1 30570 10.1038/srep30570 27484850
    [Google Scholar]
  294. Yi M.H. Liu Y.U. Liu K. Chen T. Bosco D.B. Zheng J. Xie M. Zhou L. Qu W. Wu L.J. Chemogenetic manipulation of microglia inhibits neuroinflammation and neuropathic pain in mice. Brain Behav. Immun. 2021 92 78 89 10.1016/j.bbi.2020.11.030 33221486
    [Google Scholar]
  295. Wang L. Liu K. Optogenetics: Therapeutic spark in neuropathic pain. Bosn. J. Basic Med. Sci. 2019 19 4 321 327 10.17305/bjbms.2019.4114 30995901
    [Google Scholar]
  296. Li S. Feng X. Bian H. Optogenetics: Emerging strategies for neuropathic pain treatment. Front. Neurol. 2022 13 982223 10.3389/fneur.2022.982223 36536805
    [Google Scholar]
  297. Gilbert F. Harris A.R. Kapsa R.M.I. Controlling brain cells with light: Ethical considerations for optogenetic clinical trials. AJOB Neurosci. 2014 5 3 3 11 10.1080/21507740.2014.911213
    [Google Scholar]
  298. Tsuda M. New approach for investigating neuropathic allodynia by optogenetics. Pain 2019 160 1 S53 S58 10.1097/j.pain.0000000000001506 31008850
    [Google Scholar]
  299. Forcelli P.A. Applications of optogenetic and chemogenetic methods to seizure circuits: Where to go next? J. Neurosci. Res. 2017 95 12 2345 2356 10.1002/jnr.24135 28791729
    [Google Scholar]
  300. Ju C. Park E. Kim T. Kim T. Kang M. Lee K.S. Park S.M. Effectiveness of electrical stimulation on nerve regeneration after crush injury: Comparison between invasive and non-invasive stimulation. PLoS One 2020 15 5 e0233531 10.1371/journal.pone.0233531 32453807
    [Google Scholar]
  301. What is gene therapy? 2018 Available from:https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy
  302. Dunbar C.E. High K.A. Joung J.K. Kohn D.B. Ozawa K. Sadelain M. Gene therapy comes of age. Science 2018 359 6372 eaan4672 10.1126/science.aan4672 29326244
    [Google Scholar]
  303. Puranik N. Yadav D. Chauhan P.S. Kwak M. Jin J.O. Exploring the role of gene therapy for neurological disorders. Curr. Gene Ther. 2021 21 1 11 22 10.2174/1566523220999200917114101 32940177
    [Google Scholar]
  304. Das S.K. Menezes M.E. Bhatia S. Wang X.Y. Emdad L. Sarkar D. Fisher P.B. Gene therapies for cancer: Strategies, challenges and successes. J. Cell. Physiol. 2015 230 2 259 271 10.1002/jcp.24791 25196387
    [Google Scholar]
  305. Guedon J.M.G. Wu S. Zheng X. Churchill C.C. Glorioso J.C. Liu C.H. Liu S. Vulchanova L. Bekker A. Tao Y.X. Kinchington P.R. Goins W.F. Fairbanks C.A. Hao S. Current gene therapy using viral vectors for chronic pain. Mol. Pain 2015 11 s12990-015 0018-1 10.1186/s12990‑015‑0018‑1 25962909
    [Google Scholar]
  306. Yaksh T.L. Fisher C.J. Hockman T.M. Wiese A.J. Current and future issues in the development of spinal agents for the management of pain. Curr. Neuropharmacol. 2017 15 2 232 259 10.2174/1570159X14666160307145542 26861470
    [Google Scholar]
  307. Yu H. Fischer G. Hogan Q.H. AAV-mediated gene transfer to dorsal root ganglion. Methods in Molecular Biology. Manfredsson F.P. Humana Press 2016 Vol. 1382 10.1007/978‑1‑4939‑3271‑9_18
    [Google Scholar]
  308. Xu Y. Gu Y. Xu G.Y. Wu P. Li G.W. Huang L.Y.M. Adeno-associated viral transfer of opioid receptor gene to primary sensory neurons: A strategy to increase opioid antinociception. Proc. Natl. Acad. Sci. USA 2003 100 10 6204 6209 10.1073/pnas.0930324100 12719538
    [Google Scholar]
  309. Gu Y. Cui S. Liu C. Zhao J. Li M. Li Y. Yang X. Lv B. Li M. Zhao W. Guo W. Huang J. Huang W. Qiu Z. Zhao J. Yin P. Qin T. Zhu D. Sun W. Ren K. Lu Y. Cheng X. Du L. Xiao F. Zhang Q. Wu Z. pUDK-HGF gene therapy to relieve CLI rest pain and ulcer: A Phase II, double-blind, randomized placebo-controlled trial. Hum. Gene Ther. 2021 32 15-16 839 849 10.1089/hum.2020.290 33726499
    [Google Scholar]
  310. Glorioso J.C. Fink D.J. Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol. Ther. 2009 17 1 13 18 10.1038/mt.2008.213 18841093
    [Google Scholar]
  311. Colella P. Ronzitti G. Mingozzi F. Emerging issues in AAV-Mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 2018 8 87 104 10.1016/j.omtm.2017.11.007 29326962
    [Google Scholar]
  312. Keeler A.M. Zhan W. Ram S. Fitzgerald K.A. Gao G. The curious case of AAV immunology. Mol. Ther. 2025 33 5 1946 1965 10.1016/j.ymthe.2025.03.037 40156190
    [Google Scholar]
  313. Wang J.H. Gessler D.J. Zhan W. Gallagher T.L. Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct. Target. Ther. 2024 9 1 78 10.1038/s41392‑024‑01780‑w 38565561
    [Google Scholar]
  314. Canova P.N. Charron A.J. Leib D.A. Models of herpes simplex virus latency. Viruses 2024 16 5 747 10.3390/v16050747 38793628
    [Google Scholar]
  315. Pasternak GW Pan YX Mu opioids and their receptors: Evolution of a concept. Pharmacol. Rev. 2013 65 4 1257 1317 10.1124/pr.112.007138 24076545 PMC3799236
    [Google Scholar]
  316. He L. Gooding S.W. Lewis E. Felth L.C. Gaur A. Whistler J.L. Pharmacological and genetic manipulations at the µ-opioid receptor reveal arrestin-3 engagement limits analgesic tolerance and does not exacerbate respiratory depression in mice. Neuropsychopharmacology 2021 46 13 2241 2249 10.1038/s41386‑021‑01054‑x 34257415
    [Google Scholar]
  317. Noble M Treadwell JR Tregear SJ Coates VH Wiffen PJ Akafomo C. Schoelles KM Long-term opioid management for chronic noncancer pain. Cochrane Database Syst. Rev. 2010 2010 1 CD006605 10.1002/14651858.CD006605.pub2 20091598 PMC6494200
    [Google Scholar]
  318. Shao Q. Li Y. Wang Q. Zhao J. IL-10 and IL-1β mediate neuropathic-pain like behavior in the ventrolateral orbital cortex. Neurochem. Res. 2015 40 4 733 739 10.1007/s11064‑015‑1521‑5 25617163
    [Google Scholar]
  319. Sima A.A.F. Zhang W. Sugimoto K. Henry D. Li Z. Wahren J. Grunberger G. C-peptide prevents and improves chronic Type I Diabetic polyneuropathy in the BB/Wor rat. Diabetologia 2001 44 7 889 897 10.1007/s001250100570 11508275
    [Google Scholar]
  320. Ido Y. Vindigni A. Chang K. Stramm L. Chance R. Heath W.F. DiMarchi R.D. Di Cera E. Williamson J.R. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997 277 5325 563 566 10.1126/science.277.5325.563 9228006
    [Google Scholar]
  321. Kitamura T. Kimura K. Makondo K. Furuya D.T. Suzuki M. Yoshida T. Saito M. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia 2003 46 12 1698 1705 10.1007/s00125‑003‑1232‑3 14586499
    [Google Scholar]
  322. Sima A.A.F. Zhang W. Grunberger G. Type 1 Diabetic neuropathy and C-peptide. J. Diabetes Res. 2004 5 1 65 77 10.1080/15438600490424541 15198372
    [Google Scholar]
  323. Ekberg K. Brismar T. Johansson B.L. Jonsson B. Lindström P. Wahren J. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 2003 52 2 536 541 10.2337/diabetes.52.2.536 12540632
    [Google Scholar]
  324. Ekberg K. Brismar T. Johansson B.L. Lindström P. Juntti-Berggren L. Norrby A. Berne C. Arnqvist H.J. Bolinder J. Wahren J. C-Peptide replacement therapy and sensory nerve function in type 1 Diabetic neuropathy. Diabetes Care 2007 30 1 71 76 10.2337/dc06‑1274 17192336
    [Google Scholar]
  325. Johansson B.L. Borg K. Fernqvist-Forbes E. Odergren T. Remahl S. Wahren J. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 1996 39 6 687 695 10.1007/BF00418540 8781764
    [Google Scholar]
  326. Cirillo G. Colangelo A.M. Bianco M.R. Cavaliere C. Zaccaro L. Sarmientos P. Alberghina L. Papa M. BB14, a Nerve Growth Factor (NGF)-like peptide shown to be effective in reducing reactive astrogliosis and restoring synaptic homeostasis in a rat model of peripheral nerve injury. Biotechnol. Adv. 2012 30 1 223 232 10.1016/j.biotechadv.2011.05.008 21620945
    [Google Scholar]
  327. Colangelo A.M. Bianco M.R. Vitagliano L. Cavaliere C. Cirillo G. De Gioia L. Diana D. Colombo D. Redaelli C. Zaccaro L. Morelli G. Papa M. Sarmientos P. Alberghina L. Martegani E. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J. Neurosci. 2008 28 11 2698 2709 10.1523/JNEUROSCI.5201‑07.2008 18337399
    [Google Scholar]
  328. Gjurasin M. Miklic P. Zupancic B. Perovic D. Zarkovic K. Brcic L. Kolenc D. Radic B. Seiwerth S. Sikiric P. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul. Pept. 2010 160 1-3 33 41 10.1016/j.regpep.2009.11.005 19903499
    [Google Scholar]
  329. Brines M. Dunne A.N. van Velzen M. Proto P.L. Ostenson C.G. Kirk R.I. Petropoulos I.N. Javed S. Malik R.A. Cerami A. Dahan A. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol. Med. 2014 20 1 658 666 10.2119/molmed.2014.00215 25387363
    [Google Scholar]
  330. Intondi A.B. Dahlgren M.N. Eilers M.A. Taylor B.K. Intrathecal neuropeptide Y reduces behavioral and molecular markers of inflammatory or neuropathic pain. Pain 2008 137 2 352 365 10.1016/j.pain.2007.09.016 17976913
    [Google Scholar]
  331. Diaz-delCastillo M. Woldbye D.P.D. Heegaard A.M. Neuropeptide Y and its involvement in chronic pain. Neuroscience 2018 387 162 169 10.1016/j.neuroscience.2017.08.050 28890052
    [Google Scholar]
  332. Liu H.X. Brumovsky P. Schmidt R. Brown W. Payza K. Hodzic L. Pou C. Godbout C. Hökfelt T. Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors. Proc. Natl. Acad. Sci. USA 2001 98 17 9960 9964 10.1073/pnas.161293598 11481429
    [Google Scholar]
  333. Fonseca-Rodrigues D. Almeida A. Pinto-Ribeiro F. A new gal in town: A systematic review of the role of galanin and its receptors in experimental pain. Cells 2022 11 5 839 10.3390/cells11050839 35269462
    [Google Scholar]
  334. Yu M. Fang P. Wang H. Shen G. Zhang Z. Tang Z. Beneficial effects of galanin system on Diabetic peripheral neuropathic pain and its complications. Peptides 2020 134 170404 10.1016/j.peptides.2020.170404 32898581
    [Google Scholar]
  335. Falo C. Benitez R. Caro M. Morell M. Forte-Lago I. Hernandez-Cortes P. Sanchez-Gonzalez C. O’Valle F. Delgado M. Gonzalez-Rey E. The neuropeptide cortistatin alleviates neuropathic pain in experimental models of peripheral nerve injury. Pharmaceutics 2021 13 7 947 10.3390/pharmaceutics13070947 34202793
    [Google Scholar]
  336. Morell M. Souza-Moreira L. Caro M. O’Valle F. Forte-Lago I. de Lecea L. Gonzalez-Rey E. Delgado M. Analgesic effect of the neuropeptide cortistatin in murine models of arthritic inflammatory pain. Arthritis Rheum. 2013 65 5 1390 1401 10.1002/art.37877 23371349
    [Google Scholar]
  337. Davies A.J. Rinaldi S. Costigan M. Oh S.B. Cytotoxic immunity in peripheral nerve injury and pain. Front. Neurosci. 2020 14 142 10.3389/fnins.2020.00142 32153361
    [Google Scholar]
  338. Xu C. Bai L. Chen Y. Fan C. Hu Z. Xu H. Jiang B. Effect of mutated defensin NP-1 on sciatic nerve regeneration after transection—A pivot study. Neurosci. Lett. 2016 617 283 287 10.1016/j.neulet.2015.11.003 26827715
    [Google Scholar]
  339. Yu F. Yuan Y. Xu H. Niu S. Han N. Zhang Y. Yin X. Kou Y. Jiang B. Neutrophil peptide-1 promotes the repair of sciatic nerve injury through the expression of proteins related to nerve regeneration. Nutr. Neurosci. 2022 25 3 631 641 10.1080/1028415X.2020.1792617 33054687
    [Google Scholar]
  340. de Kock M. Chetty S. Sherif Isa A. Qulu-Appiah L. An investigation on the role of oxytocin in chronic neuropathic pain in a Wistar rat model. Neurobiol. Pain 2024 16 100152 Michaela de. 10.1016/j.ynpai.2024.100152 39071531
    [Google Scholar]
  341. Zhao L. Luo H. Ma Y. Zhu S. Wu Y. Lu M. Yao X. Liu X. Chen G. An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects. Proc. Natl. Acad. Sci. USA 2022 119 31 e2204114119 10.1073/pnas.2204114119 35878019
    [Google Scholar]
  342. Hamad M.K. He K. Abdulrazeq H.F. Mustafa A.M. Luceri R. Kamal N. Ali M. Nakhla J. Herzallah M.M. Mammis A. Potential uses of isolated toxin peptides in neuropathic pain relief: A literature review. World Neurosurg. 2018 113 333 347.e5 10.1016/j.wneu.2018.01.116 29421449
    [Google Scholar]
  343. Sun T. Song W.G. Fu Z.J. Liu Z.H. Liu Y.M. Yao S.L. Alleviation of neuropathic pain by intrathecal injection of antisense oligonucleotides to p65 subunit of NF-κB. Br. J. Anaesth. 2006 97 4 553 558 10.1093/bja/ael209 16885169
    [Google Scholar]
  344. Stéphanie V. Patrick C. Philippe B. Sébastien B. Alexandre P. Antisense oligonucleotides and their use for the treatment of pain. WO2021069654A1 2021
    [Google Scholar]
  345. Borgonetti V. Galeotti N. Intranasal delivery of an antisense oligonucleotide to the RNA-binding protein HuR relieves nerve injury-induced neuropathic pain. Pain 2021 162 5 1500 1510 10.1097/j.pain.0000000000002154 33259457
    [Google Scholar]
  346. Dorn G. Patel S. Wotherspoon G. Hemmings-Mieszczak M. Barclay J. Natt F.J.C. Martin P. Bevan S. Fox A. Ganju P. Wishart W. Hall J. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 2004 32 5 e49 10.1093/nar/gnh044 15026538
    [Google Scholar]
  347. He A.T. Liu J. Li F. Yang B.B. Targeting circular RNAs as a therapeutic approach: Current strategies and challenges. Signal Transduct. Target. Ther. 2021 6 1 185 10.1038/s41392‑021‑00569‑5 34016945
    [Google Scholar]
  348. Kovanur Sampath K. Belcher S. Hales J. Thomson O.P. Farrell G. Gisselman A.S. Katare R. Tumilty S. The role of micro-RNAs in neuropathic pain—a scoping review. Pain Rep. 2023 8 6 e1108 10.1097/PR9.0000000000001108 37928202
    [Google Scholar]
/content/journals/ctmc/10.2174/0115680266417188251106114042
Loading
Navigating through Neuropathic Pain: From Pathophysiology to Present and Future Treatments
Bentham Science Publishers ; https://doi.org/10.2174/0115680266417188251106114042
/content/journals/ctmc/10.2174/0115680266417188251106114042
/content/journals/ctmc/10.2174/0115680266417188251106114042
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Stimulation therapy ; Neuropathic pain ; Gene therapy ; Peptide therapy ; Repurposed drugs ; Cannabinoid

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test